Kruczała Maksymilian Artur, Grela-Wojewoda Aleksandra, Cedrych Ida
Centrum Onkologii Instytut im. Marii Skłodowskiej-Curie Oddział w Krakowie. Klinika Nowotworów Układowych i Uogólnionych..
Ginekol Pol. 2016;87(2):131-4. doi: 10.17772/gp/59268.
Treatment of the malignant ovarian tumors remains challenging. Some of the reasons are as follows: lack of effective screening technique, usually asymptomatic early stages of the disease, which effects in detecting the disease in advanced stage, and eventually poor prognosis. Treatment of the relapse remains palliative. Inventing new drugs - like PARP inhibitors - gives hope for improvement of the treatment outcomes. This review paper presents actual knowledge on PARP inhibitors in the ovarian cancer therapy.
恶性卵巢肿瘤的治疗仍然具有挑战性。原因如下：缺乏有效的筛查技术，疾病早期通常没有症状，这导致在晚期才检测到疾病，最终预后较差。复发后的治疗仍然是姑息性的。发明新药——如聚（ADP-核糖）聚合酶（PARP）抑制剂——为改善治疗结果带来了希望。这篇综述文章介绍了PARP抑制剂在卵巢癌治疗方面的实际知识。
